Vitro Biopharma, Inc.
We are an innovative biotechnology company targeting autoimmune diseases and inflammatory disorders. (Incorporated in Nevada)
Through our proprietary platform, AlloRx Stem Cell therapy, we are developing novel cellular therapeutic candidates that are derived from culture-expanded mesenchymal stem cells (“MSCs”) sourced from the Wharton’s jelly of umbilical cords (“UCs”) donated by healthy volunteers following childbirth. In the United States, we are authorized to conduct two clinical trials under two U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) applications to assess the safety and efficacy of AlloRx Stem Cell therapy in Pitt Hopkins syndrome (“PTHS”) and post-acute sequelae to SARs-CoV-2 (“PASC”), or long COVID (“Long COVID”), and expect to commence those trials in late 2022 or early 2023 following completion of this offering.
To date, over 300 subjects have received treatment with our AlloRx Stem Cells, primarily in foreign clinical studies conducted by third parties.
Our lead clinical program is expected to focus on PTHS, a rare neurogenetic disorder primarily affecting children that is characterized by global developmental delays including autistic features, language delays, intellectual disability, neuro-irritability and significant behavioral concerns.
We generate revenue from our other technologies through a number of other activities, including providing research services and through the sale of our stem cell products as well as cosmeceuticals through InfiniVive MD, LLC (“InfiniVive MD”), our wholly owned subsidiary, which helps to alleviate our capital expenses.
*Note: Revenue and net loss figures are for the 12 months that ended April 30, 2023.
(Note: Vitro Biopharma revived its IPO (postponed on Aug. 8, 2023, a few hours before pricing) with an S-1/A filing dated Aug. 28, 2023, and the same terms: 1.82 million shares at a price range of $5.00 to $6.00 to raise $10.0 million. As of Sept. 13, 2023, the pricing date was to be determined.)
(Note: Vitro Biopharma postponed its IPO on Aug. 8, 2023, hours ahead of when the IPO had been scheduled to price after the U.S. stock market’s close.)
(Note: Vitro Biopharma set terms for its IPO on June 29, 2023, in an S-1/A filing: 1.82 million shares at a price range of $5.00 to $6.00 to raise $10.0 million.)
(Note: Vitro Biopharma changed its proposed exchange listing to the NYSE American from the NASDAQ in an S-1/A filing dated Nov. 3, 2022. The company still has not disclosed terms. Vitro Biopharma, Inc. filed its S-1 on Sept. 9, 2022.)
|Industry:||BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)|
|Address||3200 Cherry Creek Drive South, Suite 720 Denver, Colorado 80209|
|Phone Number||(855) 848-7627|
|View Prospectus:||Vitro Biopharma, Inc.|
|Revenues||$2.55 mil (last 12 months)|
|Net Income||$-6.94 mil (last 12 months)|
|Exchange||NYSE - American|
|Price range||$5.00 - $6.00|
|Est. $ Volume||$10.0 mil|
|Manager / Joint Managers||ThinkEquity|
|Expected To Trade:|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|